Key result
In patients with decompensated heart failure, levosimendan reduced the need for diuretic doses to 10% compared to 25% with other inotropes, while also improving hemodynamic stability and reducing ICU stay.
Why the study?
Does levosimendan added to standard inotropes improve hemodynamics and clinical outcomes in patients with acute decompensated heart failure post-cardiac surgery?
Observational (n=80)
No
Does levosimendan added to standard inotropes improve hemodynamics and clinical outcomes in patients with acute decompensated heart failure post-cardiac surgery?
The addition of levosimendan to standard inotropes in post-surgical patients with acute decompensated heart failure may improve hemodynamic stability and reduce ICU length of stay.
Answers are grounded in this paper and cite their sources.
May support levosimendan in decompensated HF; leaves open benefit when added to inotropes post-cardiac surgery.
Background: Levosimendan is a new-fangled calcium based sensitizer which is used to treat the patients with congestive or decompensated heart failure. The empirical study reveals that it intensifies myocardial contractility and expands coronary and peripheral vessels without affecting the diastolic function adversely. Levosimendan also performs as an opener of ATP-based K channels in vascular smooth muscle. The empirical research study shows the benefits of usage of levosimendan over other drugs in the treatment of decompensated and congestive heart failure.Methods: Levosimendan has been administered to patients with decompensated heart failure conditions. Infusion of levosimendan started with a dose of 0.1 µg/kg/min and titrated to 0.2 µg/kg/min. The systolic BP has been monitored after the administration of levosimendan to maintain stability in the patient’s BP for the initial 2-3 hours. The suggested duration of infusion of levosimendan in critical heart failure is twenty-four hours. Initially levosimendan is infused in the patients with systolic BP is more than hundred mmHg and diastolic BP is more than sixty mmHg.Results: The outcomes of the usage of Levosimendan have been studied on 80 patients with decompensated heart problems and the comparative study has also been made with other inotropes, respectively. We have also performed a trial on two groups of people named as LIVO and NON-LIVO groups. The research study proves that the usage of levosimendan is better than other inotropes. Levosimendan can be recommended in the standard treatment of patients with acute heart conditions.Conclusions: Levosimendan is offering an effective remedy to treat the patients with decompensated heart failure. In comparison to other inotropes available for the treatment of patients suffering from congestive heart ailments, levosimendan can be considered to be a safe and efficient sensitizer.
No takes yet. Share an insight, caveat, or question.
Dhaliwal et al. (2020) conducted an observational in Decompensated heart failure (n=80). Levosimendan vs. Other inotropes (noradrenaline, adrenaline, dobutamine) was evaluated on Diuretic use. In patients with decompensated heart failure, levosimendan reduced the need for diuretic doses to 10% compared to 25% with other inotropes, while also improving hemodynamic stability and reducing ICU stay.
Synapse has enriched 10 related papers. Consider them for comparative context: